Expression of smooth muscle markers in so called malignant fibrous histiocytomas

Journal of Clinical Pathology

Volumn 56, Issue 9, 2003, Pages 666-671

  Hasegawa, T ^a   Hasegawa, F ^a   Hirose, T ^b   Sano, T ^c   Matsuno, Y ^d  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BIOLOGICAL MARKER; CALDESMON; DESMIN; VIMENTIN;

ARTICLE; DERMATOFIBROMA; DIAGNOSTIC ACCURACY; ELECTRON MICROSCOPY; FIBROBLAST; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MYOFIBROBLAST; PRIORITY JOURNAL; SMOOTH MUSCLE; SMOOTH MUSCLE FIBER; TUMOR CELL; ULTRASTRUCTURE;

ACTINS; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; MUSCLE, SMOOTH; PREDICTIVE VALUE OF TESTS; SOFT TISSUE NEOPLASMS;

EID: 0042763109     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.56.9.666     Document Type: Article

References (21)

1. Hasegawa T, Yamamoto S, Nojima T, et al. Validity and reproducibility of histologic diagnosis and grading for adult soft-tissue sarcomas. Hum Pathol 2002;33:111-15.
2. Fletcher CDM. Commentary: malignant fibrous histioctyoma? Histopathology 1987;11:433-7.
3. Fletcher CDM. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumours diagnosed as pleomorphic sarcoma. Am J Surg Pathol 1992;16:213-28.
4. Hirase T, Kudo E, Hasegawa T, et al. Expression of intermediate filaments in malignant fibrous histiocytomas. Hum Pathol 1989;20:871-7.
5. Montgomery E, Fisher C. Myofibroblastic differentiation in malignant fibrous histiocytoma (pleomorphic myofibrosarcoma): a clinicopathological study. Histopathology 2001;38:499-509.
6. Hasegawa T, Yamamoto S, Yokoyama R, et al. Prognostic significance of grading and staging systems using MIB-1 score in adult patients with soft tissue sarcoma of the extremities and trunk. Cancer 2002;95:843-51.
7. Weiss SW, Goldblum JR. Leiomyosarcoma. In: Enzinger and Weiss's soft tissue tumours, 4th ed. St Louis: Mosby, 2001:727-48.
8. Watanabe K, Kusakabe T, Hoshi N, et al. h-Caldesmon in leiomyosarcoma and tumours with smooth muscle cell-like differentiation: its specific expression in the smooth muscle cell tumor. Hum Pathol 1999;30:392-6.
9. Ceballos KM, Nielsen GP, Selig MK, et al. Is anti-h-caldesmon useful for distinguishing smooth muscle and myofibroblastic tumours? Am J Clin Pathol 2000;114:746-53.
10. Hisaoka M, Wei-Qi S, Jian W, et al. Specific but variable expression of h-caldesmon in leiomyosarcomas: an immunohistochemical reassessment of a novel myogenic marker. Appl Immunohistochem Mol Morphol 2001;9:302-8.
11. Iwata J, Fletcher CDM. Immunohistochemical detection of cytokeratin and epithelial membrane antigen in leiomyosarcoma: a systematic study of 100 cases. Pathol Int 2000;50:7-14.
12. Brooks JSJ. Immunohistochemistry in the differential diagnosis of soft tissue tumours. In: Weiss SW, Brooks JSJ, eds. Soft tissue tumours. Baltimore: Williams & Wilkins, 1996:65-128.
13. Suster S. Recent advances in the application of immunohistochemical markers for the diagnosis of soft tissue tumours. Semin Diagn Pathol 2000;17:225-35.
14. Sirgi KE, Wick MR, Swanson PE. B72.3 and CD34 immunoreactivity in malignant epithelioid soft tissue tumours: adjuncts in the recognition of endothelial neoplasms. Am J Surg Pathol 1993;17:179-85.
15. Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens - evaluation of their specificity and sensitivity in the diagnosis of vascular tumours and comparison with van Willebrand factor. Mod Pathol 1994;7:B2-90.
16. Van de Rijn M, Rouse RV. CD34. A review. Appl Immunohistochem Mol Morphol 1994;2:71-80.
17. Ueda T, Araki N, Mano M, et al. Frequent expression of smooth muscle markers in malignant fibrous histiocytoma of bone. J Clin Pathol 2002;55:853-8.
18. Erlandson RA, Woodruff JM. Role of electron microscopy in the evaluation of soft tissue neoplasms, with emphasis on spindle cell and pleomorphic tumours. Hum Pathol 1998;29:1372-81.
19. Oda Y, Miyajima K, Kawaguchi K, et al. Pleomorphic leiomyosarcoma: clinicopathologic and immunohistochemical study with special emphasis on its distinction from ordinary leiomyosarcoma and malignant fibrous histiocytoma. Am J Surg Pathol 2001;25:1030-8.
20. Fletcher CDM, Van den Berg F, Molenaar WM. Pleomorphic malignant fibrous histiocytoma/undifferentiated high grade pleomorphic sarcoma. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organisation classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon, France: IARC Press, 2002:120-2.
21. Derre J, Lagace R, Nicolas A, et al. Leiomyosarcoma and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: an analysis of a series of 27 leiomyosarcomas. Lab Invest 2001;81:211-15.